Bryn Mawr Capital Management LLC Trims Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Bryn Mawr Capital Management LLC lowered its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.4% during the 4th quarter, HoldingsChannel reports. The fund owned 69,370 shares of the medical equipment provider’s stock after selling 245 shares during the period. Bryn Mawr Capital Management LLC’s holdings in Zimmer Biomet were worth $8,442,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. American Century Companies Inc. increased its stake in Zimmer Biomet by 21.2% in the 3rd quarter. American Century Companies Inc. now owns 4,863,741 shares of the medical equipment provider’s stock worth $545,809,000 after buying an additional 852,186 shares during the period. Victory Capital Management Inc. increased its stake in Zimmer Biomet by 4.9% in the 3rd quarter. Victory Capital Management Inc. now owns 3,080,463 shares of the medical equipment provider’s stock worth $345,690,000 after buying an additional 144,147 shares during the period. Allspring Global Investments Holdings LLC increased its stake in Zimmer Biomet by 16.3% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 2,760,021 shares of the medical equipment provider’s stock worth $335,895,000 after buying an additional 386,019 shares during the period. Boston Partners increased its stake in Zimmer Biomet by 29.2% in the 3rd quarter. Boston Partners now owns 2,694,832 shares of the medical equipment provider’s stock worth $302,366,000 after buying an additional 608,959 shares during the period. Finally, Northern Trust Corp increased its stake in Zimmer Biomet by 4.5% in the 3rd quarter. Northern Trust Corp now owns 2,653,334 shares of the medical equipment provider’s stock worth $297,757,000 after buying an additional 113,139 shares during the period. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Insider Buying and Selling

In related news, VP Chad F. Phipps sold 26,156 shares of Zimmer Biomet stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total value of $3,364,184.72. Following the completion of the sale, the vice president now directly owns 44,145 shares in the company, valued at approximately $5,677,929.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.95% of the stock is owned by company insiders.

Zimmer Biomet Stock Down 0.3 %

ZBH stock opened at $119.35 on Friday. The firm has a 50 day moving average of $125.98 and a 200 day moving average of $119.52. The stock has a market capitalization of $24.52 billion, a PE ratio of 24.41, a price-to-earnings-growth ratio of 2.20 and a beta of 1.01. The company has a quick ratio of 0.78, a current ratio of 1.61 and a debt-to-equity ratio of 0.39. Zimmer Biomet Holdings, Inc. has a 52 week low of $102.00 and a 52 week high of $149.25.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 EPS for the quarter, topping analysts’ consensus estimates of $2.15 by $0.05. The company had revenue of $1.94 billion during the quarter, compared to analysts’ expectations of $1.93 billion. Zimmer Biomet had a net margin of 13.85% and a return on equity of 12.79%. Zimmer Biomet’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same period last year, the business earned $1.88 EPS. Sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.80%. The ex-dividend date of this dividend is Wednesday, March 27th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 19.63%.

Analyst Ratings Changes

Several research firms recently commented on ZBH. Evercore ISI raised their price target on shares of Zimmer Biomet from $125.00 to $130.00 and gave the stock an “in-line” rating in a research note on Thursday, April 4th. StockNews.com downgraded shares of Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a research report on Monday, February 19th. TheStreet raised shares of Zimmer Biomet from a “c” rating to a “b-” rating in a research report on Thursday, February 8th. JPMorgan Chase & Co. raised their target price on shares of Zimmer Biomet from $115.00 to $125.00 and gave the company a “neutral” rating in a research report on Friday, February 9th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $140.00 target price on shares of Zimmer Biomet in a research report on Friday, February 9th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $139.39.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.